News & Views | Published:

Pediatric rheumatology

JIA, treatment and possible risk of malignancies

Nature Reviews Rheumatology volume 7, pages 67 (2011) | Download Citation

The effect of biological therapies on cancer risk in JIA is controversial owing to confounding factors such as the use of concomitant immunosuppressants. A study has shed new light on this association, but questions still remain on the effect of the disease itself and biological therapies on cancer risk.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Juvenile idiopathic arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 69, 1260–1263 (2010).

  2. 2.

    FDA. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as remicade, enbrel, humira, and cimzia). , (2008).

  3. 3.

    et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 62, 2517–2524 (2010).

  4. 4.

    et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964–975 (2010).

  5. 5.

    & Malignancies in children who initially present with rheumatic complaints. J. Pediatr. 134, 53–57 (1999).

  6. 6.

    Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis? Arthritis Rheum. 62, 2183–2184 (2010).

  7. 7.

    , , & Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. doi:10.1002/art.27741.

  8. 8.

    & Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 29, 801–807 (1986).

  9. 9.

    Paediatric Rheumatology European Society , (2010).

  10. 10.

    & International research networks in pediatric rheumatology: the PRINTO perspective. Curr. Opin. Rheumatol. 16, 566–570 (2004).

Download references

Author information

Affiliations

  1. IRCCS G Gaslini, Pediatria II Reumatologia, PRINTO, Università di Genova, Largo Gaslini 5, Genova 16147, Italy

    • Nicolino Ruperto
    •  & Alberto Martini

Authors

  1. Search for Nicolino Ruperto in:

  2. Search for Alberto Martini in:

Competing interests

The authors are on the speaker's bureau for Bristol-Myers Squibb and Novartis, while N. Ruperto is also on the speaker's bureau for Roche. A. Martini and N. Ruperto are Chairman and Senior Scientist, respectively, for the Pediatric Rheumatology International Trials Organisation (PRINTO), a non-profit organization that receives grant/research support from Abbott, Acraf S.p.A., Bristol-Myers Squibb, Centocor Ortho Biotech, Novartis, Pfizer, Roche and Xoma.

Corresponding author

Correspondence to Nicolino Ruperto.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2010.199

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing